CHRONIC OBSTRUCTIVE PULMONARY DISEASE RISK
AND SMOKING CESSATION CHANGES INDUCED
BY CHRNA5-A3 AND CHRNB3-A6 VARIATION
IN A CHINESE MALE POPULATION Zhao L1,, Zou L-Y2,, Cheng B-F3, Yu X-J4, Zou J-H5,*, Han W6,* *Corresponding Author: Dr. Wei Han, Department of Pulmonary Medicine, Qingdao Municipal Hospital,
Qingdao University, No. 5 Donghai Mid Road, Qingdao, People’s Republic of China. Tel: +86-185-
6185-7838. E-mail: sallyhan1@163.com. And: Dr. Jian-Hong Zou, Center of Diseases Control of Qingdao
Shi-Bei District, No. 3 Deping Road, Qingdao, People’s Republic of China. Tel: +86-185-6185-7599.
E-mail: 277517366@qq.com
-Long Zhao, Ling-Yan Zou contributed equally to this study. page: 51
|
RESULTS
Demographic Characteristics. As shown in Table
1, the demographics and clinical feature distribution of
the subjects show that there are significant differences
in age, daily smoking volume and the years of smoking
distribution between COPD smoking group, COPD absent
smoking group, and smoking without COPD group (p
0.001, p <0.001 and p 0.001). For still smoking patients
with COPD and non smoking patients with COPD, we
discovered marked differences with respect to age and the
years of smoking (both p 0.001). These differences were adjusted in subsequent logistic regression analyses. By
comparing the ratios of FEV1 and FEV1/FVC, smoking
COPD patients are significantly worse than the control
group, and these findings are similar in still smoking patients
with COPD and non smoking patients with COPD.
In the COPD patients, pulmonary function was classified
as mild, moderate, severe, and very severe (30.0, 31.4,
26.6 and 12.0%, respectively).
Association Between Gene Polymorphisms and
COPD Risk in Smokers. We observed all three SNPs were
in Hardy-Weinberg equilibrium in the control group (p
0.05). We genotyped the three SNPs (rs3743073, rs667282
and rs4950) in cases and controls and the results are presented
in Table 2. No significant associations were found
between rs3743073, rs667282 and rs4950 genotypes and
COPD risk after adjusting for age, BMI and smoking status.
Association Between Gene Polmorphisms and
Smoking Cessation in COPD Patients. Associations between
gene polymorphisms and smoking cessation in COPD
are shown in Table 3. The genotypes of rs667282 and rs4950
showed significant difference between cases and controls
without adjustment for potential confounding factors (age,
BMI and smoking pack-years). We adjusted for potential
confounding factors by means of logistic regression, and
then calculated the odds ratios (ORs). The CT genotype
of rs667282 demonstrated association with an increased
rate of successful smoking cessation compared with the
TT genotype [adjusted OR = 0.54, 95% confidence interval (95% CI) = 0.37-0.7, P = 0.001]. The rs4950 AG genotypes
were distinctly associated with increased rates of successful
smoking cessation (adjusted OR = 0.55, 95% CI = 0.40-0.76,
p 0.001). The effect is significant under the assumption of
an over dominant mode of inheritance (adjusted OR = 0.58,
95% CI = 0.43-0.79, p 0.001), while the similar significant
differences in rs3743073 was not found (p 0.005).
We further observed the suspicious influence factor
of CHRNA5-A3 (rs 667282) and CHRNB3-A6 (rs4950)
on smoking cessation, stratified by age, cigarettes per day
(CPD) and initiation age smoking (Table 4 and Table 5,
respectively). As show in Table 4, the success rate of quitting
smoking increased for older subjects (>60 years) (OR
= 0.66, 95% CI = 0.45-0.99, p = 0.042) and light smokers
(CPD ≤20) (OR = 0.58, 95% CI = 0.39-0.86, p = 0.007),
accompanied by rs667282 CT genotype. In Table 5, we
show that the increased rate of successful smoking cessation
with rs4950 AG genotypes was more notable in light
smokers (CPD ≤20) (OR = 0.65, 95% CI = 0.45-0.92, p =
0.016). There was no significant difference in the stratification
of age and initiation age smoking.
Association of CHRNA5-A3 and CHRNB3-A6 Poly-
morphisms with the GOLD Stage of COPD Patients.
The association of rs667282 and rs4950 polymorphisms
with the GOLD stage of COPD patients are exhibited in
Table 6. In our study, The CT genotype of rs667282 and
the AG genotype of rs4950 showed a weak association
with the GOLD stage of COPD patients.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|